⌕
West Pharmaceutical Services · WST · NYSE
Tenet 48 · Mixed
Compare
$416.42+1.24%At closeTenet 48 · Mixed
$416.42+5.12 (+1.24%)
At close: Nov 13, 2026, 4:00 PM ET· NYSE · USD
$417.00+0.58 (+0.14%)
Pre-market: Nov 16, 2026, 8:00 AM ET· last 1-minute bar

West Pharmaceutical Services (WST) Earnings Forecast

Analysts expect West Pharmaceutical Services (WST) to earn $9.49 a share in FY26, the average of 9 estimates as of Nov 13, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

16 figures withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$9.49
9 analysts
FY27 consensus EPS
$10.36
10 analysts · low $9.48, high $10.79
EPS revisions, 30 days
+5.7%
$8.98 to $9.49
Disagreement, FY26
6.6%
high to low, $9.00 to $9.63

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect West Pharmaceutical Services to earn $14.45 a share in FY30, growing about 11% a year; 4 analysts publish an estimate for FY30.

Forward P/E · FY26E
43.9×
$416.42 (as of close, Nov 13, 2026) ÷ $9.49 consensus EPS
Coverage · FY26
9 · 12
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $9.49, up 6.1% in 91 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 91 days. One step per nightly change.

−1.1%+3.1%+7.2%FY26 +6.1%FY27 +4.1%Aug 15Nov 13
EPS30 days90 daysshown aboveSince Jul 2
FY269 analysts▲ +5.7%$8.98 to $9.49▲ +6.1%$8.94 to $9.49▲ +10.2%$8.61 to $9.49
FY2710 analysts▲ +3.3%$10.03 to $10.36▲ +4.1%$9.95 to $10.36▲ +8.2%$9.58 to $10.36
Sep '269 analysts◆ 0.0%$2.20 to $2.20▲ +0.8%$2.18 to $2.20▲ +3.6%$2.12 to $2.20
Dec '268 analysts▲ +0.7%$2.28 to $2.29▲ +0.9%$2.27 to $2.29▲ +0.9%$2.27 to $2.29

Contributors at both ends of the window: FY26 10 and 9. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

At 52.6 times earnings, which is what West Pharmaceutical Services trades at today, the FY27 consensus of $10.36 works out to $545 a share.

Consensus EPS · FY27
$10.36
10 analysts · low $9.48, high $10.79 · thin coverage
Multiple · today's trailing P/E
52.6×
$416.42 (as of close, Nov 13, 2026) ÷ $7.92, the last four reported quarters, including EPS computed by Tenet
×
Receipt · WST · FY27Nov 13, 2026
Implied, a share
$545

Range on the low and high estimate: $498 to $567.

$498 low$567 high
10.36 × 52.6, to the dollar
Drag the multipleShaded: where West Pharmaceutical Services' P/E sat at each fiscal year end, FY08 to FY25. Each dot is one year.
14×20×30×40×50×60×
5-yr avg 43.7×10-yr median 45.8×today 52.6×$545 a share

Each point on the line is a multiple, and the flag is the price it implies for FY27. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 43.9 times the FY26 consensus for earnings the Street expects to grow about 12% a year to FY28. That is 3.7 times the growth rate.Show today's multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY08 to FY25 · over 18 fiscal years. The mark is the median of the last 10.
52.6× today
15.9× low62.0× high
45.8× median
Forward 43.9× is a different measure, so it is not placed on a trailing record. Today's mark is the trailing 52.6×, on the same basis as every year behind it.

How much do analysts disagree?

For FY30, estimates run from $14.07 to $14.83 around an average of $14.45, drawn by 4 analysts.

FY26E9 analysts
$9.00 to $9.63 · 6.6%
FY27E10 analysts
$9.48 to $10.79 · 12.6%
FY28E7 analysts
$11.03 to $12.72 · 14.3%
FY29E2 analysts
$13.02 to $13.72 · 5.3%
FY30E4 analysts
$14.07 to $14.83 · 5.3%

The dashed line is FY25 filed $6.79, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect West Pharmaceutical Services to earn $2.29 a share in the December quarter, the average of 8 estimates. Results are expected by Feb 16, 2027. Last quarter, which ended in June, West Pharmaceutical Services earned $2.15 a share. Analysts had expected $2.08, so it came in 3.3% higher.

$1.82
$2.29high $2.31
low $2.26
+25.9%crosses bases
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 8 analysts
Expected report
Feb 16, 2027
Expected by Feb 16. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
$825.2M
8 analysts, 822.1 to 828.4 in $M · 805.0 in the same quarter a year ago

The step from a filed quarter to a consensus crosses bases: the filed figure is the company's own GAAP number and the consensus is on the Street's basis. It is printed with both bases named, not as growth. For the March quarter, analysts expect $2.36 a share.

Does West Pharmaceutical Services usually beat or miss?

So far we have checked 10 quarters, of which 8 came in above the estimate we held. We add a quarter to this record each time West Pharmaceutical Services reports. The next report is expected by Feb 16, 2027.

We started recording estimates on Jul 2, 2026, so quarters that reported before that date cannot be checked.

Before our record
Sep '23
Dec '23
Our record, one quarter per report
+21.7%
Mar '24reaction
not held
−13.3%
Jun '24reaction
not held
+23.3%
Sep '24reaction
not held
+3.5%
Dec '24reaction
not held
+0.2%
Mar '25reaction
not held
+20.6%
Jun '25reaction
not held
+14.0%
Sep '25reaction
filing date only
−0.7%
Dec '25reaction
not held
+14.4%
Mar '26reaction
+12.9%
+3.3%
Jun '26reaction
−0.8%
reportsFeb 16
Dec '26
Mar '27
Checked so far
10 quarters
one more every report
Beat expectations
8 of 10
full details on the Earnings tab
Share price reaction
Not held
we hold only the filing date for that report, which can trail the release, so no move is shown
Typical gap vs estimate
+8.8%
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for West Pharmaceutical Services on Jul 2, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Mar '24, Jun '24, Sep '24, Dec '24, Mar '25, Jun '25, Sep '25, Dec '25, Mar '26 are drawn hollow: we hold no estimate for those quarters recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The Street expects sales to grow 5.8% in FY27 and EPS 9.2%. Most of it is sales: the net margin moves from 19.8% to 20.4%, and the implied share count from about 71.3M to 71.2M, so these numbers assume the count keeps falling.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth+5.8
Net margin change+3.2
Share count change+0.2
EPS growth+9.2
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
9 analysts publish an EPS estimate for FY26 and 12 publish revenue. Coverage thins with distance: 4 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
129
FY26E
1210
FY27E
127
FY28E
102
FY29E
64
FY30E
The FY26 panel has held 9 analysts every night since our record of it began on Jul 2, 2026.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
2.83.74.6historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 12 revenue estimates for FY26, 6 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
6.2010.6815.15historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 9 EPS estimates for FY26, 4 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed3.1—6.79————as filed52.6×
FY26E3.43.4 to 3.4▲11.2%a9.499.00 to 9.63▲39.8%a1.00.70.0712 · 943.9×
FY27E3.63.5 to 3.7▲5.8%10.369.48 to 10.79▲9.2%1.10.70.0712 · 1040.2×
FY28E3.93.8 to 4.0▲8.0%11.8811.03 to 12.72▲14.7%1.30.80.0712 · 735.0×
FY29E4.24.1 to 4.3▲7.3%13.3713.02 to 13.72n/cb1.51.00.0710 · 231.2×
FY30E4.44.3 to 4.5n/cb14.4514.07 to 14.83n/cb1.61.10.076 · 428.8×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 9 EPS estimates for FY26, 12 for revenue. Not investment advice.

What do analysts expect West Pharmaceutical Services to earn in FY26?

Analysts expect West Pharmaceutical Services to earn $9.49 a share in FY26, the average of 9 estimates as of Nov 13, 2026.

What is West Pharmaceutical Services' earnings forecast for FY27?

The FY27 consensus for West Pharmaceutical Services is $10.36 a share from 10 analysts, with a low of $9.48 and a high of $10.79, as of Nov 13, 2026.

Have analysts raised West Pharmaceutical Services' earnings estimates?

West Pharmaceutical Services' FY26 EPS consensus rose 6.1% in 91 days, from $8.94 to $9.49, as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.